This Information Disclosure Statement:
(a) ☐ accompanies the new patent application submitted herewith. 37 CFR § 1.97(a).
(b) ☐ is filed within three months after the filing date of the application or within three months after the date of entry of the national stage of a PCT application as set forth in 37 CFR § 1.491.
(c) ☐ as far as is known to the undersigned, is filed before the mailing date of a first Office Action on the merits, or before a first office action after filing a Request for Continued Examination under §1.114.
(d) ☐ is filed after the first office action and more than three months after the application's filing date or PCT national stage date of entry filing but, as far as is

known to the undersigned, prior to the mailing date of either a final rejection or a

Atty Docket No.: TWI-30900

notice of allowance, whichever occurs first, and is accompanied by either the fee
(\$180) set forth in 37 CFR § 1.17(p) or a certification as specified in 37 CFR §
1.97(e), as checked below.
(e) is filed after the mailing date of either a final rejection or a notice of allowance,
whichever occurred first, and the Issue Fee has not been paid, and is accompanied
by the fee (\$130) set forth in 37 CFR § 1.17(i)(1) and a certification as specified
in 37 CFR § 1.97(e), as checked below. This document is to be considered as a
petition requesting consideration of the information disclosure statement.
[If either of boxes (d) or (e) is checked above, the following "certification" under 37 CFR
§ 1.97(e) may need to be completed.] The undersigned certifies that:
(f) Each item of information contained in the information disclosure statement was
cited in a communication mailed from a foreign patent office in a counterpart
foreign application not more than three months prior to the filing of this
information disclosure statement.
(g) No item of information contained in this information disclosure statement was
cited in a communication mailed from a foreign patent office in a counterpart
foreign application or, to the knowledge of the undersigned after making
reasonable inquiry, was known to any individual designated in 37 CFR § 1.56(c)
more than three months prior to the filing of this information disclosure statement.
A list of the patent(s) or publication(s) is set forth on the attached Form PTO-1449
(Modified).
A copy of the items on PTO-1449 (Modified) is supplied herewith:
(h) ⊠ each (i) ☐ none (j) ☐ only those listed below:
Those patent(s) or publication(s) which are marked with an asterisk (*) in the attached
form PTO-1449 (Modified) are not supplied because they were previously cited by or submitted
to the Office in a prior application no, filed and relied upon in
this application for an earlier filing date under 35 U.S.C. § 120.
A concise explanation of relevance of the items listed on form PTO-1449 (Modified) is:
(k) not given
(l) given for each listed item

Atty Docket No.: TWI-30900

-3-	IMILIVI
(m) given for only non-English language listed item(s) [Required]	
(n) is in the form of an English language copy of a Search Report from a	foreign
patent office, issued in a counterpart application, which refers to the re	elevant
portions of the references [copy attached].	
The Examiner is reminded that a "concise explanation of the relevance" of the	e submitted
items "may be nothing more than identification of the particular figure or paragraph of	of the patent
or publication which has some relation to the claimed invention," MPEP § 609.	· ·

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR § 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR § 1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR  $\S$  1.98 and MPEP  $\S$  609 and the Examiner is respectfully requested to consider the listed references.

冈 The Commissioner is hereby authorized to charge our Deposit Account No. 50-1703, under Order No. TWI-30900, for any fees required in connection with the filing of this Information Disclosure Statement. A duplicate copy of this Notice is enclosed for this purpose. In particular, in the event that an Office Action has crossed in the mail with this Information Disclosure Statement, the Commissioner is authorized to charge the above-named deposit account for any fees required pursuant to CFR §§ 1.17(p) or 1.17(i)(1).

Respectfully submitted,

STALLMAN & POLLOCK LLP

Dated: April 2

Michael A. Stallman Reg. No. 29,444

Attorneys for Applicant(s)

Atty Docket No.: TWI-30900

APR 2 8 2003

INFORMATION DISCLOSURE CITATION (1982 Experience in necessary)

Docket Number (Optional) TWI-30900	Application Number 10/081,078		
Applicant(s) Adam E. Norton et al.			
Filing Date February 21, 2002	Group Art Unit 2877		

## **U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	5,657,121	08/12/1997	Nishina	356	327	10/16/1995
		ļ				-	

## FOREIGN PATENT DOCUMENTS

REF	DOCUMENT NUMBER	DATE	1 _	l _	I		
		DATE	COUNTRY	CLASS	SUBCLASS	YES	No
l AB	1-287528	11/20/1989	Japan	G02B	27/28	Abstract	
AC	4-358115	12/11/1992	Japan	G02B	27/28	Abstract	<u> </u>
AD	0 665 452 A1	01/27/1995	EPO	G02B	6/26		

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Date Considered

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

AND 30 2003

TESTINOLOGY CENTER 2800